Clinical trials: Leukoplakic Lesions
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Oral Leukoplakia (OL), Oral Squamous Cell Carcinoma (OSCC)
FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) is the most common cancer of the mouth and is often preceded by oral leukoplakia (OL), a white patch of the oral lining that can turn into cancer.
- Trial name
- NCT07906795
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Amina Fouad Farag
Vitamin A, Vitamin A Deficiency
Vitamin A Status in Patients With Vocal Fold Leukoplakia
This study will determine systemic vitamin A status and lesion histopathology of participants with vocal fold hyperkeratosis resulting in clinical leukoplakia.
- Conditions
- Vitamin A, Vitamin A Deficiency, Leukoplakia, Vocal Cord Neoplasm
- Trial name
- NCT05323292
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Patient at increased risk for developing a new head and neck squamous cell carcinoma are invited to take part in this study. The investigators of this trial will attempt to study the effectiveness of Celecoxib in preventing…
- Trial name
- NCT00052611
- Testing
- Celecoxib
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Leukoplakia, Oral, Benign Neoplasms
A Randomized Study of Sulindac in Oral Premalignant Lesions
The purpose of this study is to see if a drug called sulindac can prevent the development of changes in the mouth that are related to oral pre-cancer growths (oral epithelial dysplasia) or oral cancer.
- Trial name
- NCT00299195
- Testing
- sulindac
- Where
- 3 sites in United States, India
- Volunteers
- 63 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oral Cancer, Oral Lichen Planus
Artificial Intelligence Based Program to Classify Oral Cavity Findings Based on Clinical Image Analysis
This study aims to develop an AI program that can classify oral findings into Normal/variation of normal or an oral disease by clinical photos analysis, aiding in lowering the percentages of false positive and false negative…
- Conditions
- Oral Cancer, Oral Lichen Planus, Fordyce Granule, Leukoplakia
- Trial name
- NCT06325514
- Testing
- Artificial intelligence based program
- Where
- Egypt
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Cairo University
Oral Leukoplakia
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back.
- Trial name
- NCT00369174
- Testing
- rosiglitazone maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Oral Leukoplakia
Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment
Oral leukoplakia (OL) is recognized as the most common potentially malignant disorder of the oral mucosa. The pathogenesis of OL is complex and multifactorial, with oxidative stress playing a central role.
- Trial name
- NCT07331935
- Testing
- Coenzyme Q10 gel, Topical curcumin gel
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Alexandria University
Erythroleukoplakia, Leukoplakia
Pembrolizumab in Treating Participants With Leukoplakia
This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
- Conditions
- Erythroleukoplakia, Leukoplakia, Verrucous Oral Leukoplakia
- Trial name
- NCT03603223
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lichen Planus, Oral Leukoplakia
Biomarkers for Oral Cancer
The purpose is to determine the extent of genetic damage in oral mucosal lesions ascertained in the study, whether specific genotypes are associated with genetic damage observed in the oral mucosal lesions, whether the extent of…
- Conditions
- Lichen Planus, Oral Leukoplakia, Mouth Neoplasms
- Trial name
- NCT00341497
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Palatal Neoplasms, Lip Neoplasm
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Objectives Validate the OncAlert® RAPID Test by demonstrating that NPV > (1 -prevalence). Evaluate the independent and associated contribution of readily available clinical variables including age, race, gender, HPV status…
- Conditions
- Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral
- Trial name
- NCT03239834
- Testing
- OncAlert
- Where
- 26 sites in United States
- Volunteers
- 893 people
- Sponsor
- Vigilant Biosciences, Inc.
Oral Epithelial Dysplasia, Precancerous Conditions
Oral Epithelial Dysplasia Informational Needs Questionnaire
Background: Oral epithelial dysplasia (OED) is a condition with an increased risk of oral cancer. Due to the current changes in the factors associated with these diseases (because of human papillomavirus), it is expected that…
- Conditions
- Oral Epithelial Dysplasia, Precancerous Conditions, Precancerous Lesions, Oral Lichen Planus
- Trial name
- ODIN-Q (NCT04153266)
- Testing
- No intervention is planned for this study
- Where
- United Kingdom
- Volunteers
- 128 people
- Sponsor
- University College, London
Vulvar Lichen Sclerosus
The CO2RE® System for Vulvar Lichen Sclerosus
Subjects with vulvar lichen sclerosus (VLS) will undergo fractional carbon dioxide (CO2) laser treatment to the vulvar area. Subjects will be evaluated for changes in clinical signs and architectural changes associated with VLS…
- Trial name
- NCT04148651
- Testing
- The CO2RE® System
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Candela Corporation
Oral Leukoplakia, Oral Cancer
Least Invasive Nonlinear Light Microscopy
Evaluate the ability to image oral mucosa in healthy volunteer by nonlinear microscopy
- Trial name
- NCT00767442
- Where
- Taiwan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital